Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501133-23-00

Enrollment

Registered

2023-01-11

Start date

2023-05-11

Completion date

Unknown

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MIGRAINE

Brief summary

PProportion of subjects with a score less than or equal to 3 on the Simple Numerical Scale (SLA) of verbal self-assessment of patient pain (0-10), 30 minutes after the start of inhaled treatment.

Detailed description

Disappearance of any associated symptoms (nausea, photophobia, etc.): frequencies at t=0, 30, 60 and 90 minutes after the start of the oxygen or placebo session (air), Verbal Patient Pain Self-Assessment SLAs at 60 and 90 minutes (assess possible recurrence of pain), Frequency of occurrence of side effects, Average time spent in emergency rooms, Frequency of emergency painkillers

Interventions

DRUGOxigen medicinal comprimat gaz medicinal comprimat

DRUGMedicinal Air Synthetic

DRUG21.75% v/v medicinal gas

DRUGcompressed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PProportion of subjects with a score less than or equal to 3 on the Simple Numerical Scale (SLA) of verbal self-assessment of patient pain (0-10), 30 minutes after the start of inhaled treatment.	—

Secondary

Measure	Time frame
Disappearance of any associated symptoms (nausea, photophobia, etc.): frequencies at t=0, 30, 60 and 90 minutes after the start of the oxygen or placebo session (air), Verbal Patient Pain Self-Assessment SLAs at 60 and 90 minutes (assess possible recurrence of pain), Frequency of occurrence of side effects, Average time spent in emergency rooms, Frequency of emergency painkillers	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026